Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors

Non-small cell lung cancer (NSCLC) patients carrying specific EGFR kinase activating mutations (L858R, delE746-A750) respond well to tyrosine kinase inhibitors (TKIs). However, drug resistance develops within a year. In about 50% of such patients, acquired drug resistance is attributed to the enrich...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Paramita, Tan, Yee Sun, Somnay, Vishal, Mehta, Ranjit, Sitto, Merna, Ahsan, Aarif, Nyati, Shyam, Naughton, John P., Bridges, Alexander, Zhao, Lili, Rehemtulla, Alnawaz, Lawrence, Theodore S., Ray, Dipankar, Nyati, Mukesh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356576/
https://www.ncbi.nlm.nih.gov/pubmed/27612423
http://dx.doi.org/10.18632/oncotarget.11860

Ejemplares similares

Ejemplares similares